LEO RASCHE (WÜRZBURG)
GENOME-BASED TARGETED IMMUNOTHERAPY
Dept. of Haematology, Universitätsklinikum Würzburg, Würzburg, Germany
Multiple myeloma (MM) is tremendously heterogeneous disease with inter-patient - and intratumor
heterogeneity including spatial variation. Novel immunotherapies such as CAR T or T-cell engaging
bispecific antibody therapy provide game changing opportunities for relapse refractory MM and may
overcome tumor heterogeneity. In my presentation, I discuss the impact of tumor heterogeneity on
novel immunotherapies and related resistance mechanisms. I also speculate on patient selection and
potential tumor- microenvironmental signatures predicting response to immunotherapies in the near
future.
